Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
View through CrossRef
Abstract
BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. Clin Cancer Res; 21(14); 3102–4. ©2015 AACR.
See related article by Kakavand et al., p. 3140
American Association for Cancer Research (AACR)
Title: Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
Description:
Abstract
BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression.
MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi.
These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.
Clin Cancer Res; 21(14); 3102–4.
©2015 AACR.
See related article by Kakavand et al.
, p.
3140.
Related Results
Identification of a gene signature as a predictive biomarker for successfull MEK inhibition in colorectal cancer
Identification of a gene signature as a predictive biomarker for successfull MEK inhibition in colorectal cancer
Despite all advancements in cancer research and clinical practice, cancer remains a life- threatening disease with an increasing incidence. According to a 2018 WHO forecast, cancer...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
JNK activation is essential for activation of MEK/ERK signaling in IL-1β-induced COX-2 expression in synovial fibroblasts
JNK activation is essential for activation of MEK/ERK signaling in IL-1β-induced COX-2 expression in synovial fibroblasts
AbstractThe proinflammatory cytokine interleukin 1β (IL-1β) induces prostaglandin E2 (PGE2) production via upregulation of cyclooxygenase-2 (COX-2) expression in synovial fibroblas...
Abstract A6: Sustained MAPK signaling contributes to reduced sensitivity to lapatinib
Abstract A6: Sustained MAPK signaling contributes to reduced sensitivity to lapatinib
Abstract
Background: Approximately 20% to 30% of metastatic breast cancers overexpress the HER2 receptor tyrosine kinase. The standard front-line therapy for HER2-ov...
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation
Significance
Drugs that inhibit specific kinases now represent one of the main classes of targeted therapies. A majority of drug development efforts in this space focus o...
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.
e21515 Background: Skin cancer is the most common type of cancer in the US. Melanoma constitutes about 1% of all skin cancers, but it accounts for most of skin cancer related deat...